Merck (MRK) Over-Hyped in Hep C, Says Wells Fargo (GILD) (ABBV)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gilead Sciences (GILD) PT Bumped Up at Nomura
April 10, 2014 7:37 AM EDTNomura Securities analyst Ian Somaiya reiterated a Buy rating and bumped his price target on Gilead Sciences (NASDAQ: GILD) from $120 to $121, saying not all HCV drugs created equal.
Somaiya said, "We are raising our revenue estimates for Gileads HCV franchise as we... More
Maxim Remains Positive on Gilead (GILD); Sovaldi is Compelling HCV Treatment from Cost-Benefit Perspective
April 9, 2014 8:50 AM EDTGilead Sciences (Nasdq: GILD) is up early Wednesday following positive commentary out of Maxim Group. The firm has Gilead at Buy with a price target of $101.
Analyst Jason Kolbert, commented, Gilead was pilloried again yesterday for developing a drug (Sovaldi) with the highest efficacy and fewest side effects, but at a high (but not the highest) price for a new... More
Major PBM Looks to Stem Gilead Sciences' (GILD) Hepatitis C Profits
April 8, 2014 6:56 AM EDTGilead Sciences (Nasdaq: GILD) is on watch Tuesday as one major pharmacy benefits manager (PBM) is looking to stem some of its costs.
Bloomberg reported that Express Scripts (Nasdaq: ESRX) could move to... More
